NCT02778789View on ClinicalTrials.gov

Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers

CompletedOBSERVATIONAL
Enrollment

66

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

March 31, 2018

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tocilizumab

Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label

DRUG

TNF-alpha Inhibitor

Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label

Trial Locations (1)

91054

University Erlangen-Nuremberg, Medical Department 3, Rheumatology & Immunology, Erlangen

All Listed Sponsors
lead

University of Erlangen-Nürnberg Medical School

OTHER

NCT02778789 - Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers | Biotech Hunter | Biotech Hunter